Lactobacillus plantarum MYL26 induces endotoxin tolerance phenotype in Caco-2 cells

BMC Microbiology

Meei-Yn Lin¹  Chien-Tsai Huang¹  Chin-Chi Tsai¹  Shiao-Lin Lin²  Chu-Chyn Ou³  Ying-Chen Lu⁴  Yi-Heng Chiu¹ 

[1] Department of Food Science and Biotechnology, National Chung Hsing University, 250 Kuokuang Road, Taichung 40227, Taiwan;Department of Neurology, Chong Guang Hospital, MiaoLi County, Taiwan;Department of Nutrition, Chung Shan Medical University Hospital, Taichung, Taiwan;Department of Food Science, National Chiayi University, Chiayi City, Taiwan

关键词: Caco-2 cells;    Lipopolysaccharide;    Lactobacillus plantarum MYL26;   

Others  :  1143269
DOI  :  10.1186/1471-2180-13-190

 received in 2012-11-21, accepted in 2013-08-06,  发布年份 2013

【 摘 要 】

Background

Crohn's disease and ulcerative colitis are the major types of chronic inflammatory bowel disease occurring in the colon and small intestine. A growing body of research has proposed that probiotics are able to attenuate the inflammatory symptoms of these diseases in vitro and in vivo. However, the mechanism of probiotic actions remains unclear.

Results

Our results suggested Lactobacillus plantarum MYL26 inhibited inflammation in Caco-2 cells through regulation of gene expressions of TOLLIP, SOCS1, SOCS3, and IκBα, rather than SHIP-1 and IRAK-3.

Conclusions

We proposed that live/ heat-killed Lactobacillus plantarum MYL26 and bacterial cell wall extract treatments impaired TLR4-NFκb signal transduction through Tollip, SOCS-1 and SOCS-3 activation, thus inducing LPS tolerance. Our findings suggest that either heat-killed probiotics or probiotic cell wall extracts are able to attenuate inflammation through pathways similar to that of live bacteria.

【 授权许可】

   
2013 Chiu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Sorensen GV, Erichsen R, Svaerke C, Farkas DK, Sorensen HT: Risk of cancer in patients with inflammatory bowel disease and venous thromboembolism: a nationwide cohort study. Inflammatory bowel diseases 2012, 18(10):1859-1863.
• [2]Baumgart DC, Carding SR: Inflammatory bowel disease: cause and immunobiology. Lancet 2007, 369(9573):1627-1640.
• [3]Parkes GC, Sanderson JD, Whelan K: Treating irritable bowel syndrome with probiotics: the evidence. Proc Nutr Soc 2010, 69(2):187-194.
• [4]McFarland LV, Dublin S: Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008, 14(17):2650-2661.
• [5]Arseneau KO, Tamagawa H, Pizarro TT, Cominelli F: Innate and adaptive immune responses related to IBD pathogenesis. Curr Gastroenterol Rep 2007, 9(6):508-512.
• [6]Peng S, Lin JY, Lin MY: Antiallergic effect of milk fermented with lactic acid bacteria in a murine animal model. J Agric Food Chem 2007, 55(13):5092-5096.
• [7]Li CY, Lin HC, Lai CH, Lu JJ, Wu SF, Fang SH: Immunomodulatory effects of Lactobacillus and Bifidobacterium on both murine and human mitogen-activated T cells. Int Arch Allergy Immunol 2011, 156(2):128-136.
• [8]Ou CC, Lu TM, Tsai JJ, Yen JH, Chen HW, Lin MY: Antioxidative effect of lactic acid bacteria: intact cells vs. intracellular extracts. J Food Drug Anal 2009, 17(3):209-216.
• [9]Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio BC: Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005, 39(6):540-543.
• [10]Trebichavsky I, Rada V, Splichalova A, Splichal I: Cross-talk of human gut with bifidobacteria. Nutr Rev 2009, 67(2):77-82.
• [11]Golowczyc MA, Mobili P, Garrote GL, Abraham AG, De Antoni GL: Protective action of Lactobacillus kefir carrying S-layer protein against Salmonella enterica serovar Enteritidis. Int J Food Microbiol 2007, 118(3):264-273.
• [12]Ou CC, Lin SL, Tsai JJ, Lin MY: Heat-killed lactic acid bacteria enhance immunomodulatory potential by skewing the immune response toward Th1 polarization. J Food Sci 2011, 76(5):M260-M267.
• [13]Chuang L, Wu KG, Pai C, Hsieh PS, Tsai JJ, Yen JH, Lin MY: Heat-killed cells of lactobacilli skew the immune response toward T helper 1 polarization in mouse splenocytes and dendritic cell-treated T cells. J Agric Food Chem 2007, 55(26):11080-11086.
• [14]Tandon P, Moncrief K, Madsen K, Arrieta MC, Owen RJ, Bain VG, Wong WW, Ma MM: Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study. Liver Int 2009, 29(7):1110-1115.
• [15]Sanni AI, Morlon-Guyot J, Guyot JP: New efficient amylase-producing strains of Lactobacillus plantarum and L. fermentum isolated from different Nigerian traditional fermented foods. Int J Food Microbiol 2002, 72(1-2):53-62.
• [16]Kim HG, Lee SY, Kim NR, Lee HY, Ko MY, Jung BJ, Kim CM, Lee JM, Park JH, Han SH, Chung DK: Lactobacillus plantarum lipoteichoic acid down-regulated Shigella flexneri peptidoglycan-induced inflammation. Mol Immunol 2011, 48(4):382-391.
• [17]van Baarlen P, Troost FJ, van Hemert S, van der Meer C, de Vos WM, de Groot PJ, Hooiveld GJ, Brummer RJ, Kleerebezem M: Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc Natl Acad Sci USA 2009, 106(7):2371-2376.
• [18]Wells JM, Rossi O, Meijerink M, van Baarlen P: Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci USA 2011, 108(Suppl 1):4607-4614.
• [19]van Baarlen P, Troost F, van der Meer C, Hooiveld G, Boekschoten M, Brummer RJ, Kleerebezem M: Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci USA 2011, 108(Suppl 1):4562-4569.
• [20]Desreumaux P: Specific targeting of IL-6 signalling pathway: a new way to treat IBD? Gut 2000, 47(4):465-466.
• [21]Owczarek D, Cibor D, Szczepanek M, Mach T: Biological therapy of inflammatory bowel disease. Pol Arch Med Wewn 2009, 119(1–2):84-88.
• [22]West MA, Heagy W: Endotoxin tolerance: a review. Crit Care Med 2002, 30(1 Suppl):S64-S73.
• [23]Liew FY, Xu D, Brint EK, O'Neill LA: Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005, 5(6):446-458.
• [24]Tamiya T, Kashiwagi I, Takahashi R, Yasukawa H, Yoshimura A: Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T cell inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol 2011, 31(5):980-985.
• [25]Bulut Y, Faure E, Thomas L, Equils O, Arditi M: Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J Immunol 2001, 167(2):987-994.
• [26]Kobayashi K, Hernandez LD, Galán JE, Janeway CA Jr, Medzhitov R, Flavell RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002, 110(2):191-202.
• [27]Arndt PG, Suzuki N, Avdi NJ, Malcolm KC, Worthen GS: Lipopolysaccharide- induced c-Jun NH2-terminal kinase activation in human neutrophils: role of phosphatidylinositol 3-Kinase and Syk-mediated pathways. J Biol Chem 2004, 279(12):10883-10891.
• [28]Moustafa T, Fickert P, Magnes C, Guelly C, Thueringer A, Frank S, Kratky D, Sattler W, Reicher H, Sinner F, Gumhold J, Silbert D, Fauler G, Hofler G, Lass A, Zechner R, Trauner M: Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology 2012, 142(1):140-151. e12
• [29]Bondia-Pons I, Ryan L, Martinez JA: Oxidative stress and inflammation interactions in human obesity. Journal of physiology and biochemistry 2012, 68(4):701-711.
• [30]Leonard B, Maes M: Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36(2):764-785.
• [31]Baumgart DC, Thomas S, Przesdzing I, Metzke D, Bielecki C, Lehmann SM, Lehnardt S, Dorffel Y, Sturm A, Scheffold A, et al.: Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin Exp Immunol 2009, 157(3):423-436.
• [32]Vinderola G, Matar C, Perdigon G: Role of intestinal epithelial cells in immune effects mediated by gram-positive probiotic bacteria: involvement of toll-like receptors. Clin Diagn Lab Immunol 2005, 12(9):1075-1084.
• [33]Maassen CB, Claassen E: Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity. Vaccine 2008, 26(17):2056-2057.
• [34]Wahlstrom K, Bellingham J, Rodriguez JL, West MA: Inhibitory kappaBalpha control of nuclear factor-kappaB is dysregulated in endotoxin tolerant macrophages. Shock 1999, 11(4):242-247.
• [35]Kang SS, Ryu YH, Baik JE, Yun CH, Lee K, Chung DK, Han SH: Lipoteichoic acid from Lactobacillus plantarum induces nitric oxide production in the presence of interferon-gamma in murine macrophages. Mol Immunol 2011, 48(15–16):2170-2177.
• [36]Shimosato T, Kimura T, Tohno M, Iliev ID, Katoh S, Ito Y, Kawai Y, Sasaki T, Saito T, Kitazawa H: Strong immunostimulatory activity of AT- oligo- deoxynucleotide requires a six-base loop with a self-stabilized 5′-C…G-3′ stem structure. Cell Microbiol 2006, 8(3):485-495.
• [37]Pathmakanthan S, Li CK, Cowie J, Hawkey CJ: Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon. J Gastroenterol Hepatol 2004, 19(2):166-173.
• [38]Takeda K, Akira S: TLR signaling pathways. Semin Immunol 2004, 16(1):3-9.
• [39]Kondo T, Kawai T, Akira S: Dissecting negative regulation of Toll-like receptor signaling. Trends Immunol 2012, 33(9):449-458.
• [40]Naka T, Fujimoto M, Tsutsui H, Yoshimura A: Negative regulation of cytokine and TLR signalings by SOCS and others. Adv Immunol 2005, 87:61-122.
• [41]Talaei F, Atyabi F, Azhdarzadeh M, Dinarvand R, Saadatzadeh A: Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences 2013, 49(4):712-722.
• [42]Frolkis A, Dieleman LA, Barkema H, Panaccione R, Ghosh S, Fedorak RN, Madsen K, Kaplan GG: Environment and the inflammatory bowel diseases. Can J Gastroenterol = J Can Gastroenterologie 2013, 27(3):e18-e24.